<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1692B8A6C74B4BA69A0467CD2FA1D271" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 887 IH: Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2021</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2021-02-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 887</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20210205">February 5, 2021</action-date><action-desc><sponsor name-id="L000582">Mr. Lieu</sponsor> (for himself, <cosponsor name-id="C001080">Ms. Chu</cosponsor>, and <cosponsor name-id="N000147">Ms. Norton</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to enhance medical device communications and ensure device cleanliness.</official-title></form><legis-body id="HB26D21BCA87B47F8A859C7C85540825C" style="OLC"><section id="HC99F45E2670947D69AF42E2B6EA7988A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2021</short-title></quote> or the <quote><short-title>DEVICE Act of 2021</short-title></quote>.</text></section><section id="H42F068DF7E2549D8BED6D9F2F83B693B"><enum>2.</enum><header>Reporting requirement for design and reprocessing instruction changes</header><subsection id="HC7CA28DBE0BD4F4EAC53B201F6FDC0C5"><enum>(a)</enum><header>Adulteration</header><text display-inline="yes-display-inline">Section 501 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref>) is amended by inserting after paragraph (j) the following:</text><quoted-block display-inline="no-display-inline" id="HEDD2EF52EC7246B8A609D9E738FFEC88" style="OLC"><subsection id="HEE6D86ADB5214CA599C67AA8A70DFA61"><enum>(k)</enum><text display-inline="yes-display-inline">If it is a device with respect to which the manufacturer is in violation of the reporting requirement in section 510(r) (relating to design and reprocessing changes).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HF8A7222734954B58A7FD989AC9A52B0D"><enum>(b)</enum><header>Requirement</header><text display-inline="yes-display-inline">Section 510 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360</external-xref>) is amended by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="HFFC5E890ADA946FE950D2B8CFD308244" style="OLC"><subsection id="H0DE740B80ACA4CF3BB529B73DEA4A404"><enum>(r)</enum><header>Reporting requirement for device design changes</header><text display-inline="yes-display-inline">Before making a change to the design of a device, or the reprocessing instructions of a device, that is marketed in interstate commerce, the manufacturer of the device shall give written notice of the change to the Food and Drug Administration.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H0317143A78C54F1D8E66CC8C46D8ED07"><enum>3.</enum><header>Reporting requirement for certain communications to foreign health care providers</header><subsection id="HF5FA4DD39FCC4302AA152A86920EEE38"><enum>(a)</enum><header>Adulteration</header><text display-inline="yes-display-inline">Section 501 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref>), as amended by section 2 of this Act, is further amended by inserting after paragraph (k) the following:</text><quoted-block display-inline="no-display-inline" id="HA116C10E76E041D1AC248D1BA6FCE48C" style="OLC"><subsection id="H7F6D04E8C62A4B53AEF8BD0F4AB7A973"><enum>(l)</enum><text display-inline="yes-display-inline">If it is a device with respect to which the manufacturer is in violation of the reporting requirement in section 510(s) (relating to communications to foreign health care providers).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HBE01B562ED804FF2B0B3F66A19D4C4EC"><enum>(b)</enum><header>Requirement</header><text display-inline="yes-display-inline">Section 510 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360</external-xref>), as amended by section 2 of this Act, is further amended by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="HA1405F19B8334AC7B48A5DBB48948BFC" style="OLC"><subsection id="H424CA28CB85E4AE0878CB615CA15AE00"><enum>(s)</enum><header>Reporting requirement for certain communications to foreign health care providers</header><paragraph id="HBA605FBB0BBC478E891BF6296F0440BB"><enum>(1)</enum><header>Requirement</header><text display-inline="yes-display-inline">The manufacturer of a device that is marketed in interstate commerce shall give written notice to the Food and Drug Administration of any communication described in paragraph (2) not more than 5 calendar days after making such communication.</text></paragraph><paragraph id="H924DD5C9535E4403B103E78CD7482722"><enum>(2)</enum><header>Communication described</header><text>A communication is described in this paragraph if the communication—</text><subparagraph id="H133301EF604141B9B10FB6B8F1551E63"><enum>(A)</enum><text>is made by the manufacturer of the device or an affiliate of the manufacturer;</text></subparagraph><subparagraph id="H4C34119AE129408888552E4B4E5AB238"><enum>(B)</enum><text>relates to a change to the design of the device, a change to the recommended reprocessing protocols, if any, for the device, or a safety concern about the device; and</text></subparagraph><subparagraph id="H4BAE2AE3E38949AA814ACA0D733B22F9"><enum>(C)</enum><text>is widely disseminated (including on a voluntary basis) to health care providers in a foreign country.</text></subparagraph></paragraph><paragraph id="H8B02620482604F999A84342F1395AB1C"><enum>(3)</enum><header>Affiliate</header><text display-inline="yes-display-inline">In this subsection, the term <term>affiliate</term> means a business entity that has a relationship with a second business entity if, directly or indirectly—</text><subparagraph id="H13DF04C1E4904AE29B726392FA643C3F"><enum>(A)</enum><text>one business entity controls, or has the power to control, the other business entity; or</text></subparagraph><subparagraph id="H7DAFE50E384247AA9FB1701961BBC924"><enum>(B)</enum><text>a third party controls, or has the power to control, both of the business entities.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H0E4C40FBD637401BAEB2BB920DA75C42"><enum>4.</enum><header>Rapid assessment tests intended to ensure proper reprocessing</header><subsection id="HB03F4A028F1D442D9700F2B0AB2AB34F"><enum>(a)</enum><header>Inclusion in device definition</header><text display-inline="yes-display-inline">Section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>) is amended—</text><paragraph id="H8779366A2E2E43C280E382C5CC48349D"><enum>(1)</enum><text>in paragraph (h)—</text><subparagraph id="H025C2A538729451D94F3CEA1F9E0D203"><enum>(A)</enum><text>in subparagraph (2), by striking <quote>or</quote> at the end;</text></subparagraph><subparagraph id="HC2F619A6999B47B8AE3103A9F6F72793"><enum>(B)</enum><text>in subparagraph (3), by striking <quote>and</quote> at the end and inserting <quote>or</quote>; and</text></subparagraph><subparagraph id="H67DAAA7019794FAEB36135A517F9A65E"><enum>(C)</enum><text>by inserting after subparagraph (3) the following:</text><quoted-block display-inline="no-display-inline" id="H30C143A902434A4CBFCA91AA02DBFE9F" style="OLC"><paragraph id="H8ED9B13438ED4744884C830C3A012D0B"><enum>(4)</enum><text display-inline="yes-display-inline">a rapid assessment test intended to ensure the proper reprocessing of a reusable device (as defined in paragraph (ss)), and</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HBC0C0920102D4649884421CB304F93A4"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="HA7DA16E4166F457783F492AFD23B9311" style="OLC"><subsection id="HE3E4E2B0A8DB4361AB9CD958C5CB0D88"><enum>(ss)</enum><text display-inline="yes-display-inline">The term <term>reusable device</term> means a device that—</text><paragraph id="HCC708F85BEA743829A74D7D8D5ECDA88"><enum>(1)</enum><text>is intended to be used more than one time; and</text></paragraph><paragraph id="H3B293654407E4AE9A8224041553487DD"><enum>(2)</enum><text display-inline="yes-display-inline">must be sanitized (whether through cleaning, disinfection, or sterilization) to ensure that the device is safe and effective for such intended use.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HFF9124B3D42B41FC89A346C68663905E"><enum>(b)</enum><header>Instructions for use and validation data</header><text display-inline="yes-display-inline">Section 510 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360</external-xref>), as amended by sections 2 and 3 of this Act, is further amended by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="HEB0D2EF2B6024C1596E1A0C08C0690F3" style="OLC"><subsection id="H45F710A13D024C61834F11829B4541CA"><enum>(t)</enum><header>Instructions for use and validation data</header><paragraph id="H9EED91E875C84BA49A1288AB5A3AFC9F"><enum>(1)</enum><header>Initial list</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this subsection, the Secretary shall by regulation develop and publish a list of types of rapid assessment tests described in section 201(h)(4) for which reports under subsection (k) must include—</text><subparagraph id="H070B66A6B4F64D72B4AE9A952D3C7D81"><enum>(A)</enum><text>instructions for use that have been validated in a manner specified by the Secretary; and</text></subparagraph><subparagraph id="HE71E764CD58D4AD6BD8117AE1C085776"><enum>(B)</enum><text>validation data, of the types specified by the Secretary.</text></subparagraph></paragraph><paragraph id="HAE06D8DF8A8B4F8592B83C2C383AF825"><enum>(2)</enum><header>Updates</header><text display-inline="yes-display-inline">The Secretary shall by regulation periodically update the list required by paragraph (1).</text></paragraph><paragraph id="H11F5FB3103F9423395281935BE360F1C"><enum>(3)</enum><header>Enforcement</header><text>Beginning on the date of publication of the initial list under paragraph (1), the Secretary shall not accept any notification under subsection (k) for clearance of a type of rapid assessment test that is included on such list unless such notification includes instructions for use and validation data in accordance with paragraph (1).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

